Amneal and Shilpa introduce Boruzu in US for cancer treatment
Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or intravenous administration, offering a…
All articles by
-
-
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseases
Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of priority review…
-
BioVersys secures patent claims in China for BV100
Biopharmaceutical company BioVersys has announced the grant of key patent claims in China for BV100, the intravenous formulation of rifabutin.…
-
Apollomics and LaunXP agree on NSCLC treatment in Asia
Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib combined with an epidermal…
-
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as…
-
Macau approves IASO Bio’s multiple myeloma therapy
The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene autoleucel…
-
Weill Cancer Hub East launches to transform treatment
The Weill Cancer Hub East, a collaborative initiative formed by Weill Cornell Medicine, Princeton University, The Rockefeller University and the…
-
Genmab’s Tivdak approved in Japan for advanced cervical cancer
Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced…
-
Ionis and Sobi agree on olezarsen commercialisation
Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended…
-
Tribune gains funds to advance scar tissue therapies
Tribune Therapeutics has secured €37m ($39.9m) in seed and Series A funding to propel its therapy portfolio aimed at the…